Update shared on17 Aug 2025
Fair value Increased 5.63%The upward revision in Apollo Hospitals Enterprise's price target reflects improved profitability, as evidenced by a higher net profit margin and a lower future P/E, resulting in a new consensus fair value of ₹8,587.
What's in the News
- Board meeting scheduled to consider unaudited Q1 FY26 financial results and potential acquisition of Parkway Healthcare's 50% stake in Gleneagles PET-CT Private Limited.
- In-principle approval granted for a composite scheme involving the demerger of pharmacy and digital health businesses into a new entity, intended to become an Indian Owned and Controlled Company and list within 18-21 months, with Apollo retaining a 15% stake.
- Plans underway to acquire the remaining 74.5% stake in Apollo Medicals Pvt Ltd. to consolidate front-end pharmacy operations under the new entity.
- Apollo reportedly exploring sale of its Apollo Cradle And Children Hospital Private Limited, valued at INR 10-12 billion, engaging Allegro Capital to find buyers.
- Announced major expansions in Bengaluru, adding 700 beds with planned greenfield and acquired hospitals, as part of a broader plan to add over 4,300 beds in the next 4 years with over INR 80 billion in project costs.
Valuation Changes
Summary of Valuation Changes for Apollo Hospitals Enterprise
- The Consensus Analyst Price Target has risen from ₹8130 to ₹8587.
- The Future P/E for Apollo Hospitals Enterprise has significantly fallen from 50.99x to 45.64x.
- The Net Profit Margin for Apollo Hospitals Enterprise has risen from 8.68% to 9.11%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.